Mount Sinai Launches App and First Campaign of The Resilience Project to Develop New Treatments and Preventive Care for Diseases
Lyme Campaign Seeks Participants Who Are ‘Resilient’ to the Tick-borne Disease
To learn more about The Resilience Project, watch a short video here.
Researchers at Mount Sinai have launched a new app in conjunction with the Lyme Campaign to uncover new treatments and preventive strategies for tick-borne diseases by studying people who are resistant or resilient to them.
The campaign, which is seeking thousands of participants, is the first undertaken by The Resilience Project, a large multi-phase effort that includes researchers collaborating with “resilient” people who should have a disease—whether through exposure or genetics—but lack typical signs or symptoms.
While most efforts to cure diseases focus on identifying the factors that make people susceptible to disease, the Mount Sinai team is turning that notion on its head to examine those that protect people.
“Through the Resilience Project, we want to give everyone a chance to collaborate in the discovery and decoding of people with potential protective factors against disease,” says Jason Bobe, MSc, Associate Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai and Principal Investigator of the Resilience Project Study. “We hope people will rally to help find individuals who escaped a disease and connect them to research.”
As part of the Lyme Campaign, the project will focus on identifying people who are resistant or resilient to ticks and tick-borne diseases including Lyme disease. The project is seeking individuals with laboratory test results that indicate an exposure to the bacteria that cause Lyme disease, but who have never been treated with antibiotics and lack typical signs and symptoms of the disease. The project is also looking for individuals with high exposure to ticks—such as forestry workers, gardeners, or landscapers—who either experience bite reactions including pain, swelling, and itching, or those who become immune to ticks and are no longer bitten by bugs.
The campaign will include partnerships with collaborating labs, disease foundations, patient groups, and other mission-driven organizations. These ongoing efforts include analyzing hundreds of outdoor workers on Long Island who have high exposure to ticks with Ben Luft, MD, at the Stony Brook University School of Medicine; collaborating with Uri Laserson, PhD, Assistant Professor of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai, to develop and evaluate a profiling technology to characterize how an individual’s immune system responds to exposure to the pathogen that causes Lyme disease; and joining forces with George Church, PhD, and Ting Wu, PhD, Professors of Genetics at Harvard Medical School, to decode what protects Lyme-resilient people from the infection or disease progression.
While exposure to Lyme disease is the project’s first area of focus, Mount Sinai researchers recognize people can be resilient to diseases in a variety of ways including genetic, environmental, and community-based factors. The Resilience Project is using its newly launched app to recruit participants across many diseases and conditions, including:
- Genetic escapers: People who have genetic mutations that typically cause disease but who lack typical signs and symptoms, such as a person who carries a significant genetic risk for early-onset Alzheimer’s disease.
- Positive outliers: People with rare traits or remarkable health experiences that may unlock new knowledge about the prevention or treatment of a disease in others, such as individuals with lifelong levels of high LDL (“bad”) cholesterol who do not have coronary artery calcification.
- Infection resisters or survivors: People with exposure to infection who resist or recover in an exceptional manner, such as a person who has been exposed to the virus SARS-CoV-2, tested positive through a medical test, but remains without symptoms associated with the disease COVID-19 for at least two weeks.
As one of the often-cited cases of an infection resister, Stephen Crohn was exposed to HIV in the 1970s and 1980s but never tested positive for the infection or developed AIDS. Scientists later discovered he had genetic changes that rendered his white blood cells impenetrable to HIV and blocked the infection. This finding would eventually help scientists develop a drug that prevented the spread of the virus in people already infected. The Resilience Project aims to find participants today like Mr. Crohn who want to share their unique experience with resistance or resilience to a disease and help advance research on novel prevention and treatment strategies.
“People who volunteer for research often find their way into a research study as part of a path to diagnosis or treatment for an illness,” says Noura Abul-Husn, MD, PhD, Chief of the Division of Genomic Medicine; Clinical Director of the Institute for Genomic Health; Associate Professor of Medicine and Genetics at the Icahn School of Medicine at Mount Sinai; and a co-investigator of the Resilience Project Study. “We aim to systemically search for positive outliers: people who may not be spending much time in academic clinical settings where they would more likely be invited to collaborate with health researchers.”
Potential participants can learn more about different types of resilience, share their own stories, and enroll in the study through the website and app, The Resilience Project. The Lyme Campaign is funded by the Bay Area Lyme Foundation.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.